Source comparison
Comparison: Tesamorelin + Ipamorelin vs Other Peptide Stacks
Researchers selecting peptide combinations for growth hormone modulation face multiple options, each with distinct receptor targets, side effect profiles, and regulatory considerations. The table below compares the tesamorelin + ipamorelin blend for muscle gro
This comparison does not assign a generated winner or score.
- Researchers selecting peptide combinations for growth hormone modulation face multiple options, each with distinct receptor targets, side effect profiles, and regulatory considerations. The table below compares the tesamorelin + ipamorelin blend for muscle growth against commonly studied alternatives based on mechanism, selectivity, and evidence quality.
- Tesamorelin + Ipamorelin
- GHRH receptor agonist + selective ghrelin receptor agonist
- High selectivity; minimal cortisol/prolactin elevation
- Injection site reactions (10–15%), transient hyperglycemia (5–8%), rare: fluid retention
- Phase 3 RCTs for tesamorelin; animal models for combination
- Best-studied option with regulatory approval pathway for tesamorelin; true synergistic mechanism
- CJC-1295 (DAC) + Ipamorelin
- Long-acting GHRH analogue + selective ghrelin agonist
- High selectivity; extended half-life (6–8 days) complicates dosing
- Similar to tesamorelin but prolonged; potential for sustained IGF-1 supraphysiological levels
- Limited human RCT data; mostly observational and case reports
- Longer duration may increase cumulative GH exposure but lacks tesamorelin's clinical trial foundation
- GHRP-6 + Mod GRF (1-29)
- Non-selective ghrelin agonist + short-acting GHRH analogue
- Low selectivity; significant ghrelin activity increases appetite and cortisol
- Increased appetite (60–80%), cortisol elevation (20–30%), water retention
- Early-phase human trials; mechanism well-characterized but limited body composition endpoints
- Potent GH release but appetite stimulation contradicts fat loss goals; cortisol spike impairs MPS
- Sermorelin + GHRP-2
- GHRH fragment (1-29) + non-selective ghrelin agonist
- Moderate selectivity; GHRP-2 elevates cortisol less than GHRP-6
- Flushing (15–20%), cortisol elevation (moderate), injection site reactions
- Decades of clinical use; primarily anti-aging literature rather than body composition RCTs
- Established safety profile but mechanism overlap with tesamorelin; GHRP-2 less selective than ipamorelin
- Hexarelin + CJC-1295 (No DAC)
- Potent ghrelin agonist + short-acting GHRH analogue
- Low selectivity; rapid receptor desensitization with hexarelin
- Significant cortisol/prolactin elevation, rapid tachyphylaxis (loss of effect within 4–6 weeks)
- Limited human data; primarily animal models
- Strongest acute GH pulse but unsustainable; receptor desensitization makes it unsuitable for cycles >4 weeks
- The tesamorelin + ipamorelin blend for muscle growth offers the most favorable selectivity and evidence profile among peptide stacks studied for body recomposition. Tesamorelin is the only GHRH analogue with FDA approval (for HIV-associated lipodystrophy), providing a regulatory and safety foundation absent from research-only compounds. Ipamorelin's selective ghrelin receptor agonism avoids the appetite stimulation and cortisol spikes that undermine other secretagogues. CJC1295 Ipamorelin 5MG 5MG represents an alternative GHRH approach, while researchers can explore the broader implications of growth hormone modulation through our Tesamorelin Ipamorelin Growth Hormone Stack designed specifically for body composition research.